Literature DB >> 33622410

HDL cholesterol efflux capacity and lipid profile in patients with systemic sclerosis.

Iván Ferraz-Amaro1, Esmeralda Delgado-Frías1, Vanesa Hernández-Hernández1, Hiurma Sánchez-Pérez1, Laura de Armas-Rillo2, Estefanía Armas-González1, José David Machado3, Federico Diaz-González4,5.   

Abstract

OBJECTIVE: It is well established that patients with systemic sclerosis (SSc) have a disrupted lipid profile and an increased cardiovascular risk. Cholesterol efflux capacity (CEC), the ability of high-density lipoprotein (HDL)-cholesterol to accept cholesterol from macrophages, has been linked to cardiovascular events. The aim of this study was to establish whether CEC and lipid profile were impaired in SSc patients with respect to controls and whether these changes were associated with disease-related data.
METHODS: Cross-sectional study encompassed 188 individuals: 73 SSc patients and 115 controls. CEC, using an in vitro assay, and lipoprotein serum concentrations were assessed in patients and controls. A multivariable analysis was performed to study the differences in CEC between patients and controls, and if SSc-related data could explain such differences.
RESULTS: The multivariable analysis adjusted for demographic characteristics, cardiovascular risk factors, and lipid-related molecules showed that total cholesterol (beta coefficient: - 22 [95%CI - 37 to - 7], p = 0.004), triglycerides (beta coefficient: 24 [95%CI 2-47], p = 0.033), lipoprotein A (beta coefficient: 22 [95%CI 2-43], p = 0.033), and CEC (beta coefficient: - 6 [95%CI - 10 to - 2]%,p = 0.002) were significantly different between patients and controls. Skin thickness, as assessed by modified Rodnan skin score, was independently associated with a lower CEC (beta coefficient: - 0.21 [95%CI - 0.37 to - 0.05]%, p = 0.011) after multivariable adjustment.
CONCLUSION: SSc patients show an abnormal lipid profile with respect to controls including CEC. Skin thickness is independent and inversely associated with CEC in SSc patients.

Entities:  

Keywords:  Cholesterol efflux capacity; Modified Rodnan skin score; Systemic sclerosis

Mesh:

Substances:

Year:  2021        PMID: 33622410      PMCID: PMC7901093          DOI: 10.1186/s13075-021-02443-9

Source DB:  PubMed          Journal:  Arthritis Res Ther        ISSN: 1478-6354            Impact factor:   5.156


  32 in total

1.  Systemic sclerosis is not associated with clinical or ambulatory blood pressure.

Authors:  N A Zakopoulos; V Th Kotsis; E J Gialafos; C M Papamichael; V Ch Pitiriga; D N Mitsibounas; M E Mavrikakis
Journal:  Clin Exp Rheumatol       Date:  2003 Mar-Apr       Impact factor: 4.473

2.  Lipoprotein[a] and the lipid profile in patients with systemic sclerosis.

Authors:  Giuseppe Lippi; Paola Caramaschi; Martina Montagnana; Gian Luca Salvagno; Alessandro Volpe; Giancesare Guidi
Journal:  Clin Chim Acta       Date:  2005-08-19       Impact factor: 3.786

3.  Proprotein convertase subtilisin/kexin type 9 in rheumatoid arthritis.

Authors:  Ivan Ferraz-Amaro; Raquel López-Mejías; Begoña Ubilla; Fernanda Genre; Beatriz Tejera-Segura; Antonia M de Vera-González; Agustín F González-Rivero; Jose M Olmos; Jose L Hernández; Javier Llorca; Miguel A González-Gay
Journal:  Clin Exp Rheumatol       Date:  2016-08-31       Impact factor: 4.473

Review 4.  HDL Cholesterol Efflux Capacity: Cardiovascular Risk Factor and Potential Therapeutic Target.

Authors:  Anish Bhatt; Anand Rohatgi
Journal:  Curr Atheroscler Rep       Date:  2016-01       Impact factor: 5.113

Review 5.  Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport.

Authors:  Robert S Rosenson; H Bryan Brewer; W Sean Davidson; Zahi A Fayad; Valentin Fuster; James Goldstein; Marc Hellerstein; Xian-Cheng Jiang; Michael C Phillips; Daniel J Rader; Alan T Remaley; George H Rothblat; Alan R Tall; Laurent Yvan-Charvet
Journal:  Circulation       Date:  2012-04-17       Impact factor: 29.690

6.  Subclinical Atherosclerosis in Systemic Sclerosis: Not Less Frequent Than Rheumatoid Arthritis and Not Detected With Cardiovascular Risk Indices.

Authors:  Gulsen Ozen; Nevsun Inanc; Ali U Unal; Fatmanur Korkmaz; Murat Sunbul; Mustafa Ozmen; Servet Akar; Rabia Deniz; Salim Donmez; Omer N Pamuk; Pamir Atagunduz; Kursat Tigen; Haner Direskeneli
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-09-02       Impact factor: 4.794

7.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

8.  The risk of cardiovascular disease in systemic sclerosis: a population-based cohort study.

Authors:  Ada Man; Yanyan Zhu; Yuqing Zhang; Maureen Dubreuil; Young Hee Rho; Christine Peloquin; Robert W Simms; Hyon K Choi
Journal:  Ann Rheum Dis       Date:  2012-08-17       Impact factor: 19.103

9.  To match or not to match in epidemiological studies--same outcome but less power.

Authors:  Tomas Faresjö; Ashild Faresjö
Journal:  Int J Environ Res Public Health       Date:  2010-01-26       Impact factor: 3.390

10.  Prevalence of sarcopenia in systemic sclerosis: assessing body composition and functional disability in patients with systemic sclerosis.

Authors:  Elise Siegert; Christine March; Lindsey Otten; Alexander Makowka; Emelina Preis; Frank Buttgereit; Gabriela Riemekasten; Ursula Müller-Werdan; Kristina Norman
Journal:  Nutrition       Date:  2018-04-03       Impact factor: 4.008

View more
  1 in total

Review 1.  Lipid Alterations in Systemic Sclerosis.

Authors:  Zuzanna Gogulska; Zaneta Smolenska; Jacek Turyn; Adriana Mika; Zbigniew Zdrojewski
Journal:  Front Mol Biosci       Date:  2021-12-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.